Positive expression of cyclin D1 is an indicator for the evaluation of the prognosis of breast cancer

被引:1
作者
Guo, Liying [1 ]
Liu, Sha [1 ]
Jakulin, Adina [1 ]
Yilamu, Dilimina [1 ]
Wang, Bowei [2 ]
Yan, Jinghong [3 ]
机构
[1] Xinjiang Med Univ, Affiliated Hosp 1, Digest & Vasc Ctr, Dept Breast Canc, 137 Liyushan Rd, Urumqi 830054, Xinjiang Autono, Peoples R China
[2] Xinjiang Med Univ, Affiliated Hosp 1, Dept Pathol, Urumqi 830054, Xinjiang Autono, Peoples R China
[3] Xinjiang Med Univ, Affiliated Hosp 1, Dept Med Records, Urumqi 830054, Xinjiang Autono, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2015年 / 8卷 / 10期
关键词
Breast cancer; cyclin D1; molecular subtype; prognosis; ESTROGEN-RECEPTOR; POOR-PROGNOSIS; OVEREXPRESSION; PREDICTS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Aims: The present study is to detect the expression of cyclin D1 in different clinical molecular subtypes in breast cancer, and to analyze its relationship to the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (Her-2), tumor size, clinical stages, histological grades, age of menarche, and prognosis. Methods: In the present study, we retrospectively reviewed the clinical information of 226 patients with breast cancer who were hospitalized at The First Affiliated Hospital of Xinjiang Medical University between January 2000 and December 2012. Immunohistochemical method was used to detect the expression of cyclin D1 in breast cancer tissues. Pearson's Chi-square test was performed to compare the expression of cyclin D1 under different clinical indicators, and under different immune indexes and subtypes. Spearman rank correlation method was used to analyze the correlation between cyclin D1 expression and ER, PR, Her-2, tumor size, clinical stages, histological grades and age of menarche. Kaplan-Meier was employed to calculate the survival time of tumor-free survival time. Log-rank method was used to analyze the survival curves. Results: The expression of cyclin D1 was not significantly correlated to tumor size, clinical stages, histological grades, age of menarche, or PR, but was correlated to ER. Higher cyclin D1 positive rate corresponded to higher ER positive rate. The expression of cyclin D1 was negatively correlated to Her-2 expression (P < 0.05). Higher cyclin D1 positive rate corresponded to lower Her-2 positive rate. In cyclin D1 positive group, the percentage of Luminal A type was the highest. In cyclin D1 negative group, the percentage of Luminal B type was the highest. Higher cyclin D1 positive rate led to longer tumor-free survival time. Conclusions: The expression of cyclinD1 is significantly correlated to ER and Her-2. Positive expression of cyclin D1 suggests good prognosis, and can be used as an indicator for the evaluation of the prognosis of breast cancer.
引用
收藏
页码:18656 / 18664
页数:9
相关论文
共 25 条
  • [1] [Anonymous], 2010, PRACTICAL PREVENTIVE
  • [2] Cai B, 2008, CHINA PRACTICAL MED, V3, P33
  • [3] Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Carey, Lisa A.
    Perou, Charles M.
    Livasy, Chad A.
    Dressler, Lynn G.
    Cowan, David
    Conway, Kathleen
    Karaca, Gamze
    Troester, Melissa A.
    Tse, Chiu Kit
    Edmiston, Sharon
    Deming, Sandra L.
    Geradts, Joseph
    Cheang, Maggie C. U.
    Nielsen, Torsten O.
    Moorman, Patricia G.
    Earp, H. Shelton
    Millikan, Robert C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21): : 2492 - 2502
  • [4] Collecchi P, 1999, INT J CANCER, V84, P139, DOI 10.1002/(SICI)1097-0215(19990420)84:2<139::AID-IJC8>3.0.CO
  • [5] 2-Y
  • [6] Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1
  • [7] Fan Y, 2010, CLIN MISDIAGNOSIS MI, V23, P101
  • [8] β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
    Geyer, Felipe C.
    Lacroix-Triki, Magali
    Savage, Kay
    Arnedos, Monica
    Lambros, Maryou B.
    MacKay, Alan
    Natrajan, Rachael
    Reis-Filho, Jorge S.
    [J]. MODERN PATHOLOGY, 2011, 24 (02) : 209 - 231
  • [9] Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO
  • [10] 2-Q